Coagulation activation appears to play a role in tumor progression. Low-molecular-weight heparin (LMWH) may influence tumor growth and LMWHs have been shown to beneficially influence tumor response to chemotherapy. In a phase II study using docetaxel plus enoxaparin in 25 patients with advanced breast cancer, fibrin monomer, transforming growth factor-beta 1 (TGF-b 1 ) and response rates were evaluated. Enoxaparin was administered at a daily dose of 0, 5 or 1.0 mg/kg and docetaxel at 35-45 mg/m 2 once weekly. Nine patients achieved a partial response (36%) and nine patients (36%) had stable disease. The median time to progression was 11.5 weeks (range 5-51 weeks), and 16 weeks combining patients with partial remission and stable disease. One major bleed occurred. Patients with partial remission had a significant decrease of TGF-b 1 and fibrin (P < 0.05). A significant correlation between TGF-b 1 and fibrin monomer was also seen in all subgroups independent of clinical response. The most frequent toxicities were granulocytopenia, asthenia, transient peripheral edema and temporary hot flushes. In conclusion, docetaxel plus enoxaparin was quite active and well tolerated in patients with advanced breast cancer. These preliminary data suggest further clinical research using chemotherapy plus enoxaparin as an antitumor therapy in advanced breast cancer is warranted. Blood Coagul Fibrinolysis 18:415-423 ß 2007 Lippincott Williams & Wilkins. Blood Coagulation and Fibrinolysis 2007, 18:415-423 
Introduction
Despite an enlarged repertoire of anticancer agents, breast cancer remains the second most frequent cause of cancer-related death in western women [1] , requiring new treatment options. Angiogenesis is an essential step in tumor growth and metastasis [2] and quite different from that in normal tissues, as indicated by the presence of immature vessels, areas of necrosis and increased vascularity [3, 4] . A close relationship between angiogenesis and tissue factor is well documented [5] , and activation of the coagulation system is frequent in cancer patients and appears to play a role in promoting tumor progression [6] [7] [8] [9] [10] . Tumor cells directly activate coagulation by expressing high levels of procoagulants, such as tissue factor [11] [12] [13] [14] [15] [16] [17] , and surface fibrin formation can shield tumor cells from the immune system [18] .
Data from large randomized trials in patients with venous thrombosis [19, 20] suggest that cancer-related mortality is lower when patients receive low-molecular-weight heparin (LMWH) [21] rather than unfractionated heparin. LMWH also seems to prolong time to progression [22, 23] , reduce mortality and prolong median survival in patients with advanced solid malignancy [24] . Heparin interferes with fibrin formation, a key regulator of angiogenesis [25] . Also, heparin may influence tumor growth by binding to several angiogenic factors [8, 26] .
It therefore seems a rational therapeutic strategy to evaluate LMWH in cancer patients as an antitumor agent in addition to conventional chemotherapy; in fact, LMWH has been shown to beneficially influence tumor response to chemotherapy [23, 24, 27] and, in addition, has a low bleeding rate [22] .
To our knowledge, only three published studies have used chemotherapy plus LMWH as an antitumor strategy. The first study compared a standard chemotherapy regimen with and without unfractionated heparin in the treatment of small-cell lung cancer; addition of heparin yielded better response rates and better survival [27] . The second randomized study also used a standard chemotherapy regimen, with and without LMWH in small cell lung cancer [23] , leading to a better progressionfree survival. In the third, nonrandomized study, patients with metastatic nonsmall-cell lung cancer were treated with docetaxel plus enoxaparin [28] . All these studies were performed in chemotherapy-naïve patients. To the best of our knowledge, therefore, no data are available on adding LMWH to chemotherapy in pretreated patients with defined cancer entities.
The dysregulation of transforming growth factor-beta 1 (TGF-b 1 ) pathways has been implicated in the pathogenesis of breast cancer and other malignancies [29] [30] [31] [32] [33] [34] . TGF-b 1 secretion by tumor cells enhances tumor progression by increasing extracellular matrix production/ degradation, inducing angiogenesis, and inhibiting effector mechanisms of immune surveillance [35] . TGF-b 1 plasma levels in untreated nonsmall lung cancer patients decrease during therapy with docetaxel and enoxaparin [28] . TGF-b 1 data in breast cancer are inconsistent, describing both reduced [36, 37] and enhanced [38, 39] levels during chemotherapy. Ivanovic et al. [40] reported a subgroup of six patients with advanced breast cancer with a relationship between plasma levels of TGF-b 1 and tumor response. Furthermore, 12 of 13 patients with advanced nonsmall-cell lung cancer who received docetaxel plus enoxaparin and had a response or stable disease showed a reduction in TGF-b 1 [28] . This suggests that TGF-b 1 levels might correlate with tumor response in advanced disease. Interestingly, tumor growth can be induced by tissue factor [6] [7] [8] , which might constitute a paracrine response to tumor cell-derived molecules of the TGF-b family [12] .
Since no studies in pretreated and advanced breast cancer patients for combined tumor therapy with regular chemotherapy plus LMWH are available, we designed an open phase II dose determination trial to evaluate the safety and feasibility of using a LMWH (enoxaparin) during weekly chemotherapy with docetaxel in advanced and pretreated breast cancer. We designed this study based on the hypothesis that enoxaparin might be safely used to interfere with tumor progression and metastasis, leading to a prolonged time to tumor progression. The courses of TGF-b 1 , fibrin generation (as measured by fibrin monomer formation) and anti-activated factor X (anti-FXa) activity were also evaluated.
Patients and methods

Patients
The study was approved by the institutional review board and the national regulatory institution (Swissmedic). All patients gave written informed consent.
Inclusion criteria were: advanced breast cancer that failed to respond or progressed after no more than two other chemotherapies; evaluable disease; at least 4 weeks since any previous chemotherapies; any radiotherapy was completed 2 weeks prior to enrolment; white blood cell count above 3.0 gl; platelet count above 150 g/l; bilirubin less than 25 mmol/l; aspartate-aminotranferase below three times the upper limit of normal; alkaline phosphatase below five times the upper limit of normal; and creatinine less than 120 mmol/l. Exclusion criteria were: age younger than 18 years, pregnancy or lactation period; Eastern Cooperative Oncology Group performance status above 2; life expectancy below 3 months; previous taxane-based chemotherapy; history of brain metastases; history of allergic reactions to any heparin or taxanes; contraindications to therapy with heparin; any thrombosis during the past 6 months; any history of central nervous system hemorrhage; prolonged anticoagulation (with exception of thrombosis prophylaxis or immobilization) during the past 6 months; and active therapy with antiplatelet agents.
Treatment plan
Dose determination of docetaxel and enoxaparin was performed in consecutive dose-level cohorts of up to six patients according to a dosing schedule based on earlier dose-finding studies [41] : level 1: docetaxel 35 mg/m 2 intravenously, enoxaparin 0.5 mg/kg per day subcutaneously; level 2: docetaxel 35 mg/m 2 intravenously, enoxaparin 1.0 mg/kg per day subcutaneously; level 3: docetaxel 45 mg/m 2 intravenously, enoxaparin 0.5 mg/kg per day subcutaneously; level 4: docetaxel 45 mg/m 2 intravenously, enoxaparin 1.0 mg/kg per day subcutaneously. Docetaxel was given weekly during six consecutive weeks followed by 2 weeks without treatment (15 patients), or three consecutive weeks followed by 1 week without treatment (nine patients). Enoxaparin was given as daily subcutaneous self-injection and was continued during docetaxel treatment breaks (i.e. it was continued during the whole study period) (for dose modifications, see below).
Documentation of the clinical response
Patients were actively monitored weekly or when side effects occurred; they underwent tumor response evaluation after 8 weeks of combined chemotherapy plus LMWH therapy. Patients with objective response or stable disease of the tumor continued treatment for three cycles or until disease progression occurred. The following parameters were used for evaluation of tumor response: imaging procedures (computed tomography, scintigraphy, X-ray and ultrasound; 18 patients), palpable and measurable skin metastasis or lymph node-metastasis (12 patients), cancer antigen 15-3, cancer antigen 125 (22 patients), and indirect indications for tumor progression such as ascites or acroedema (four patients, only in combination with other measurable parameters).
Partial remission was defined as a 50% or greater reduction in the size of all measurable lesions or markers, no new lesions appearing. Stable disease was defined as a reduction less than 50% or an increase less than 25% of all measurable lesions or markers. The appearance of any new lesion or an increase of at least 25% constituted progressive disease.
Toxicity and dose modification
Docetaxel doses were only given with neutrophils greater than 1.5 g/l. For patients with at least grade II toxicity according to World Health Organization grading [42] , docetaxel was postponed for 1 week. If grade III or IV toxicity occurred, docetaxel was decreased by 15% with subsequent treatments. If the same toxicity still reoccurred, the patient went off study. Enoxaparin was continued if docetaxel was postponed.
Full-dose enoxaparin (1.0 mg/kg per day) was only given with platelet levels above 75 g/l. With platelet counts below 75 g/l, enoxaparin was held until the platelet count had recovered. Patients with major hemorrhages went off study. For patients with minor hemorrhages, enoxaparin therapy was to be halted temporarily until bleeding had stopped.
Laboratory evaluation
Blood was weekly drawn using a vacuum system (Vacutainer, BD, Franklin Lakes, New Jersey, USA). Blood was centrifuged immediately at 1600 Â g and 228C for 20 min and plasma was stored at À708C until use. Special care was taken to leave the cell pellet undisturbed when pipetting the plasma into aliquoting tubes. 
Results
Patient characteristics
All patients were postmenopausal, median age 58 years. Ductal adenocarcinoma was the predominant histology (68%), followed by invasive lobular carcinoma (16%), mixed (8%) and other forms (8%). Twenty patients had undergone breast surgery and axillary dissection; 13 patients had received one chemotherapy and 11 patients two different chemotherapies. One patient was enrolled into the study although she had had no prior chemotherapy. She completed all three cycles of chemotherapy and had a time to progression of 36 weeks. Eighteen patients had had hormonal therapy, and 16 patients had had a radiation therapy before enrollment (Table 1) . At the time of evaluation of the first 25 patients enrolled, three patients were still alive and off study, 22 patients had died.
Safety and side effects
One major bleeding occurred during study treatment ( Table 2 ). This patient developed focal neurological deficits and partial aphasia during therapy. Magnetic resonance imaging showed a skull metastasis locally protruding into the brain and infiltrating the orbital muscles. Minimal intrametastatic and perimetastatic bleeding was also seen. According to the protocol, the patient went off study. After radiotherapy but without any other local interventions, the neurological symptoms disappeared. Minor hemorrhages were seen in 10 patients; one of these was bleeding into a skin metastasis, which in fact represented central necrosis of the metastasis, and one patient had blood tinged rectal discharge with known hemorrhoids. Thirteen patients reported nasal secretion tinged with blood, which was not classified as bleeding.
Enoxaparin had to be stopped for platelet levels less than 75 g/l in two patients. In one of them, progressive Docetaxel, enoxaparin and breast cancer Seeholzer et al. 417 bone marrow carcinosis lead to a further fall to 15 g/l (enoxaparin was not reinstituted) and the patient died 2 weeks after stopping the therapy due to progressive disease. Enoxaparin was paused and reinstituted after 1 week in the other patient; no further episode of thrombocytopenia was observed.
Granulocytopenia occurred in eight patients (six grade III, two grade II), but resolved quickly when docetaxel was paused for 1 week. Seven out of eight patients had granulocytopenia grade II or III with docetaxel at 45 mg/m 2 . The dose of docetaxel was reduced in five of those eight patients. One patient had a pre-existing slight anemia (grade I).
The most frequent nonhematological adverse events with the combined treatment were asthenia, nausea, dysesthesia and dysgeusia. Eight patients had temporary hot flushes. Seven patients showed transient peripheral edema, but one patient had generalized edema that required hospitalization and the study treatment had to be stopped. Nail changes were seen in four patients, starting 14 weeks after treatment initiation and still present 2 months after the end of treatment. Alopecia (grade 2-3) was seen in two patients. Potential docetaxel-related skin toxicity was seen in three patients. Four patients had epiphora, and one of them developed a cannaliculus-stenosis (a known side effect with docetaxel) requiring surgical treatment.
There were two allergic reactions (grade I and II, flush and dyspnea) with docetaxel therapy that improved quickly after treatment with clemastin and ranitidine.
Other potential side effects induced cessation of docetaxel in three cases: one with fluid retention, one with asthenia, and one with combined asthenia and hematotoxicity ( Fig. 1) .
Efficacy
Nine patients (36%) had partial remission and nine patients (36%) showed stable disease, suggesting a clinical benefit in 72% of the patients. Six patients (24%) showed initial signs of tumor progression. The median time to progression could be calculated for 22 patients and was 11.5 weeks (range 5-51 weeks). For three patients, the time to progression could not be calculated: two started other chemotherapy before tumor progression occurred and one patient went off study during the first week for personal reasons. For patients with partial remission, the median time to progression was 17 weeks (mean 24.7 weeks, range 9-51 weeks) and for partial remission or stable disease was 16 weeks (mean 20.1 weeks, range 6-51 weeks). The median survival at time of evaluation was 15 months (mean 16.4 months, range 2-37 months): two patients were still alive. One-year survival was 56%.
No differences in clinical outcome were observed with different dosages of enoxaparin or docetaxel. In four of six patients (66%) with progressive disease, the tumor was negative for estrogen receptors, and in five of six patients (83%) it was negative for progesterone receptors. In patients with partial remission or stable disease, 77% had positive or borderline positive estrogen receptors and progesterone receptors (positive/ borderline/negative: estrogen receptors 10/1/7, progesterone receptors 8/3/7).
Transforming growth factor-beta 1 TGF-b 1 levels were measured in 23 patients. The mean plasma level prior to treatment was 11 103 pg/ml with considerable variations (range 4767-27 180 pg/ml). No correlation between baseline levels and clinical response, age or hormone receptor status was found.
Patients with partial response had a significant decrease of the TGF-b 1 from baseline to best response levels during therapy (P ¼ 0.0101). Combining patients with partial response or stable disease, a significant reduction was also seen (P ¼ 0.0028) (Fig. 2) . The other groups had no significant changes (Fig. 3) . The course of TGF-b 1 was neither associated with different dosages of enoxaparin nor docetaxel.
Fibrin monomer, anti-FXa activity and thrombotic events Mean baseline fibrin monomer was 28.7 mg/ml (range 2.41-99.47 mg/ml). The course from baseline levels to best response in patients with partial remission showed a significant decrease (P ¼ 0.037); patients with stable disease showed a decrease with a strong trend to significant difference (P ¼ 0.08), while in the group with progressive disease no such decrease was seen (P ¼ 0.48). The average reduction from baseline to best response was À79% for partial remission and À61% for stable disease patients. Overall, a weak but significant correlation between fibrin monomer and TGF-b 1 was seen (r ¼ 0.255, P ¼ 0.003). This correlation was also maintained when patients were stratified for treatment response (partial remission, r ¼ 0.3495, P ¼ 0.009; stable disease, r ¼ 0.295, P ¼ 0.0139; progressive disease, r ¼ 0.4541, P ¼ 0.0061) (Fig. 4) .
The average level of anti-FXa activity in all patients was 0.23 IU/ml (range 0-2.09 IU/ml). The difference of anti-FXa-activity between the two groups with higher and lower dose enoxaparin is not significant. No patients had clinical evidence of thrombosis during treatment with docetaxel and enoxaparin, but two patients developed deep venous thrombosis after enoxaparin was stopped (one subclavian/internal jugular vein thrombosis 4 weeks after the study period; one splenic vein thrombosis 8 months after the study period).
Discussion
The aim of this open phase II study was to evaluate the safety and feasibility of combined docetaxel and enoxaparin therapy in pretreated patients with advanced breast cancer and the course of TGF-b 1 and fibrin monomer levels during this therapy.
In our patient population with 96% of patients being pretreated, the overall response rate was 36% with overall median time to progression of 17 weeks (average 24.7 weeks). An earlier study of 30 patients with metastatic breast cancer and weekly docetaxel at 35 mg/m 2 showed a response rate of 33%, but only 60% of these patients were pretreated [43] . Raff et al. [44] found a partial response rate of 21% in 35 HER2/neu-negative patients, with 77% of these patients having prior chemotherapy. Hainsworth et al. [45] found 36% partial response and 36% stable disease with weekly docetaxel; less than 50% of these patients were pretreated.
Our study therefore shows encouraging response rates in a heavily pretreated patient population (52% with one chemotherapy and 44% with two chemotherapies, 72% of all patients with hormonal therapies, 80% with breast surgery and axillary dissection, 64% with radiation therapy) when compared with other trials using weekly docetaxel. This suggests a potential benefit of the combination of docetaxel with enoxaparin.
A firm conclusion can obviously not be drawn, however, since this was a phase II trial.
No clinically evident thrombosis occurred during the study period. One subclavian and internal jugular vein thrombosis occurred 4 weeks after stopping enoxaparin after a surgical procedure (despite reinitiated regular peri-interventional LMWH prophylaxis). We speculate that this thrombosis might have been prevented if enoxaparin had been continued.
Side effects in our study were comparable with the previously mentioned studies in chemotherapy-naïve patients (for example [28] ). Docetaxel was stopped in three cases because of side effects but all side effects were temporary and disappeared soon after the end of therapy. One patient developed a protruding skull metastasis and a minimal hemorrhage into the metastasis occurred. It is thus unclear that this bleeding was indeed caused by the use of enoxaparin; nevertheless, as per definition by the protocol, this bleeding was qualified as a 'major' bleed.
Overall, the low frequency of side effects emphasizes the safety of the given LMWH in combination with regular chemotherapy, at least with the regimen investigated in this trial. This concurs with the findings of other clinical studies [46] [47] [48] .
Dysregulation of TGF-b 1 pathways has been implicated in the pathogenesis of breast cancer [29, 38, 40, 49, 50 ]. It appears that inhibiting TGF-b 1 secretion from neoplastic and/or stromal cells may slow tumor progression. In our study, TGF-b 1 plasma levels in patients with partial remission decreased during treatment. Whether the reduction in TGF-b 1 is the consequence of a tumor response that would have occurred even without LMWH therapy remains to be elucidated. TGF-b 1 levels in our study suggest that their course correspond with clinical outcome.
Other investigators have shown that markers of coagulation activation such as D-dimer correlate with tumor volume, progression rate and survival in patients with metastatic breast cancer [50] and lung cancer [28] . Levels of D-dimer and fibrin monomer correlate well with the currently commercially available assays [51] . In line with the finding that fibrin potentially protects tumor cells from the immune system [18] are the results by Beer et al. [52] showing that survival correlates with fibrin monomer levels. The fact that decreasing fibrin monomer levels were seen in our study in patients with partial remission and stable disease support an association of fibrin generation with tumor growth; but it remains to be clarified whether the rate of fibrin generation correlates with progression rate during therapy.
Overall, the safety and potential efficacy of combining chemotherapy with enoxaparin in advanced breast cancer is supported by the data of our trial. Our findings suggest that a randomized trial to define the role of LMWH as antitumor agents in advanced breast cancer patients would be a reasonable next step.
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